SterisCare Pharma is pleased to announce the commercial launch of AtorisCare 20mg, expanding our lipid management portfolio to serve a broader range of patient needs across cardiology clinics and hospitals.
AtorisCare 20mg contains Atorvastatin Calcium 20mg, a potent HMG-CoA reductase inhibitor indicated for the management of primary hypercholesterolaemia and mixed dyslipidaemia in patients requiring a higher dose than available in our existing AtorisCare 10mg formulation.
Clinical Rationale
Clinical evidence consistently supports higher-intensity statin therapy for patients at moderate-to-high cardiovascular risk. AtorisCare 20mg fills this therapeutic gap, enabling physicians to initiate or intensify statin therapy without switching brands.
Availability
AtorisCare 20mg is now available through all authorised SterisCare distribution channels. Healthcare professionals may contact our medical affairs team for product monographs and clinical data packages.
